W18 Progress Toward a Reliable Domestic Supply of Molybdenum-99
The NRC has issued construction permits for new facilities designed for the domestic production of molybdenum-99, a precursor to the principal isotope in nuclear medicine for diagnostic imaging—technetium-99m. In preparation for anticipated construction activities and submissions of operating license applications, the NRC staff is updating its construction inspection procedures, developing operation inspection procedures, finalizing guidance, and considering the impact of proposed rulemakings on potential medical isotope facilities. This session details the progress toward licensing and regulating medical isotope facilities and shares the perspectives of regulators, licensees, and other stakeholders.
- Alexander Adams, Branch Chief, Division of Licensing Projects, NRR/NRC
- Steven Lynch, Project Manager, Division of Licensing Projects, NRR/NRC
- Jeff Chamberlin, Director, Material Management and Minimization, Office of Conversion, National Nuclear Security Administration
- Carolyn Haass, Chief Executive Officer, Northwest Medical Isotopes
- J. David Robertson, Associate Director, University of Missouri Research Reactor
- Gregory Piefer, Chief Executive Officer, SHINE Medical Technologies, Inc.
- Cindy Montgomery, Project Manager, Division of Licensing Projects, NRR/NRC tel: 301-415-3398, e-mail: Cindy.Montgomery@nrc.go
Page Last Reviewed/Updated Monday, June 04, 2018